Liqing Jin
About
In The Last Decade
Liqing Jin
40 papers receiving 3.8k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Molecular Biology 2.2k
- Hematology 1.4k
- Oncology 1.3k
- Immunology 860
- Cancer Research 364
Countries citing papers authored by Liqing Jin
This map shows the geographic impact of Liqing Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqing Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqing Jin more than expected).
Fields of papers citing papers by Liqing Jin
This network shows the impact of papers produced by Liqing Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqing Jin. The network helps show where Liqing Jin may publish in the future.
Co-authorship network of co-authors of Liqing Jin
This figure shows the co-authorship network connecting the top 25 collaborators of Liqing Jin. A scholar is included among the top collaborators of Liqing Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liqing Jin. Liqing Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia breakdown → | 150 |
| 4 | 7 | |
| 5 | 8 | |
| 6 | 1 | |
| 7 | 74 | |
| 8 | 32 | |
| 9 | 390 | |
| 10 | Anti-CD9 antibody, AR40A746.2.3, inhibits tumor growth in pancreatic and breast cancer models and recognizes CD9 on CD34+CD38- leukemic cancer stem cells. | 2 |
| 11 | Targeting of CD44 eradicates human acute myeloid leukemic stem cells breakdown → | 920 |
| 12 | Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. | 81 |
| 13 | Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity breakdown → | 718 |
| 14 | 159 | |
| 15 | 77 | |
| 16 | 120 | |
| 17 | 6 | |
| 18 | 12 | |
| 19 | 11 | |
| 20 | 9 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.